Spira Analyzes the Use of Durvalumab in Unresectable Stage III NSCLCSeptember 7th 2020
Alex Spira, MD, PhD, director, Virginia Cancer Specialists, Phase I Trial Program, Fairfax, VA, discussed the use of durvalumab as treatment of a 63-year-old male with unresectable stage III non–small cell lung cancer.
McKean Uses Updated Data to Support Utilization of Cemiplimab for CSCC TherapySeptember 7th 2020
Treatment options for a 69-year-old patient with poorly differentiated, infiltrative, cutaneous squamous cell carcinoma was discussed by Meredith McKean, MD, MPH and a group of physicians.
Johnson Examines Osimertinib in the Frontline Setting for NSCLCSeptember 5th 2020
The case of a 73-year-old Asian patient diagnosed with non–small cell lung cancer and an EGFR exon 19 deletion was discussed during a virtual Case Based Peer Perspectives event, led by Melissa L. Johnson, MD.
Kris Details Use of Immunotherapies After Lung Cancer ProgressionSeptember 4th 2020
During a virtual Case Based Peer Perspectives event, Mark G. Kris, MD, attending physician, Thoracic Oncology Service, William and Joy Ruane chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discussed molecular testing for a 59-year-old patient with poorly differentiated adenocarcinoma of the lung, as wells as the treatment options for the patient.
Quinn Explores Treating Metastatic CRPC in Men With Germline or Somatic MutationsAugust 30th 2020
During a virtual Case Based Peer Perspectives event, David I. Quinn, MD, MBBS, PhD, reviewed the case of a 60-year old male patient with metastatic castration-resistant prostate cancer.